MDL No. 3180 gathers federal Dupixent lawsuits alleging the drug caused or accelerated cutaneous T-cell lymphoma after treatment for presumed eczema or asthma.
Dupixent is the brand name for dupilumab, an inflammation drug, and cutaneous T-cell lymphoma is a rare skin lymphoma that can look like eczema. The outcome will likely turn on expert proof, not on broad claims about the drug. Courts will test how studies link the drug to lymphoma, how doctors tell eczema from early lymphoma, and whether the warning was adequate.
Table of Contents
- Who does MDL 3180 cover?
- What warning question will the court face?
- Why do the studies point in different directions?
- Why will biopsy timing and expert rules matter?
Who does MDL 3180 cover?
The U.S. Judicial Panel on Multidistrict Litigation states in its transfer order that it created MDL No. 3180 on June 4, 2026. It centralized the federal cases in the District of New Jersey before Judge Zahid Quraishi.
The cases focus on cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome, according to the TorHoerman Law guide. The core claim is new or faster lymphoma after Dupixent use for presumed eczema, asthma, or related inflammation. Plaintiffs name Sanofi, Regeneron Pharmaceuticals, and Genzyme as defendants, according to Reich & Binstock. They allege the companies knew of a possible lymphoma link and failed to warn patients and doctors.
What warning question will the court face?
The U.S. Food and Drug Administration database shows in its labeling record that the Dupixent label warns about hypersensitivity, conjunctivitis, keratitis, arthralgia, and other events. The same labeling record contains no specific lymphoma or cutaneous T-cell lymphoma warning in 2025-2026 labeling.
That gap frames the failure-to-warn claim. Plaintiffs will argue a lymphoma warning was needed sooner and would have changed treatment choices. Defendants will argue the label matched what regulators required based on known risks. That dispute makes prescribing history and warning timing central for each patient.
Why do the studies point in different directions?
A 2024 Journal of the American Academy of Dermatology cohort by Hasan and colleagues is summarized by the American Academy of Allergy, Asthma & Immunology in its expert answer. It followed 22,888 eczema patients treated with dupilumab and over 1.1 million untreated patients. Treated patients had about four times higher odds of cutaneous T-cell lymphoma, with an odds ratio of 4.10. A large 2025 TriNetX study reported the opposite direction in Frontiers in Medicine in its cohort report.
It compared 801,508 matched cases and controls and found dupilumab did not raise lymphoma risk versus other systemic treatments. Risk tended lower with dupilumab. The clash leaves causation open for expert debate. Plaintiffs will stress the higher odds in eczema patients, while defendants will stress the larger matched comparison against active treatments.
Why will biopsy timing and expert rules matter?
Early cutaneous T-cell lymphoma mimics eczema, so doctors may first diagnose eczema and prescribe Dupixent. Experts therefore debate "unmasking," meaning the drug revealed lymphoma that was already present but misdiagnosed. AJMC reports that a French Delphi panel reviewed 547 dupilumab-linked cases across 51 studies and set biopsy and T-cell-clonality testing rules for atypical or late-onset eczema. That process affects proof in two ways.
A prompt biopsy can show what the skin disease was and when it changed. A late biopsy leaves room to dispute whether Dupixent caused disease or only preceded its discovery. Regeneron, Sanofi-Aventis U.S., and Genzyme state in their transfer-motion response that neither FDA nor the European Medicines Agency has found that Dupixent causes or accelerates the disease. Reliability of expert methods and adequacy of warnings will likely decide which cases survive pretrial review.
- Keep every eczema, asthma, and dermatology record with start dates for Dupixent.
- Keep pathology reports, biopsy slides, and T-cell-clonality results in one file.
- List prior creams, light therapy, and systemic drugs with dates and reasons for change.
- Note when rash spread, thickened, formed tumors, or failed to improve.